# A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers

> **NCT06289920** · PHASE1 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 47 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** BR3005
- **DRUG:** BR3005-1
- **DRUG:** BR3005-2

## Key facts

- **NCT ID:** NCT06289920
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-02
- **Primary completion:** 2024-03-28
- **Final completion:** 2024-03-28
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2024-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06289920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06289920, "A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of "BR3005" and Co-administration of "BR3005-1" and "BR3005-2" Under Fasting Conditions in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06289920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*